Literature DB >> 32881763

Neuroinflammatory Biomarkers Associated With Mild Traumatic Brain Injury History in Special Operations Forces Combat Soldiers.

Jacob R Powell1, Adrian J Boltz, Jamie P DeCicco, Avinash Chandran, Stephen M DeLellis, Marshall L Healy, Shawn F Kane, James H Lynch, Gary E Means, Anthony C Hackney, Jason P Mihalik.   

Abstract

BACKGROUND: Special Operations Forces (SOF) combat soldiers are frequently exposed to blast and blunt neurotrauma, most often classified as mild traumatic brain injury (mTBI). Repetitive mTBI may increase the risk of developing long-term neurological sequelae. Identifying changes in neuroinflammatory biomarkers before chronic conditions emerge could serve as preliminary evidence of developing neuropathology.
OBJECTIVE: To determine the effects of mTBI history, lifetime mTBI incidence, and recency on blood biomarker concentrations of axonal protein neurofilament light (NfL), glycolytic enzyme neuron-specific enolase (NSE), astrocyte-expressed S100 calcium-binding protein B (S100B), and neurotrophic cytokine interleukin-6 (IL-6) in healthy, active duty SOF combat soldiers.
METHODS: Self-reported mTBI history/recency and fasted blood samples were collected in this cross-sectional study of 104 asymptomatic SOF combat soldiers. Biomarker concentrations were quantified using commercial enzyme-linked immunosorbent assays. Mann-Whitney U and Kruskal-Wallis tests were used to compare groups. Post hoc tests with appropriate corrections were conducted as warranted.
RESULTS: Soldiers with mTBI history had higher NSE concentrations than those without (z = -2.60, P = .01). We also observed significant main effects of lifetime mTBI incidence on NSE (χ(3) = 9.52, P = .02) and S100B (χ(3) = 8.21, P = .04) concentrations and a significant main effect of mTBI recency on NfL concentration (χ(2) = 6.02, P = .049).
CONCLUSION: The SOF combat soldiers with mTBI history had increased NSE. Longitudinal studies in this population are needed due to between-subject heterogeneity in biomarker concentrations. The NfL concentrations in our SOF combat soldiers-regardless of mTBI history or recency-were similar to values previously reported in civilian acute TBI patients.

Entities:  

Year:  2020        PMID: 32881763     DOI: 10.1097/HTR.0000000000000598

Source DB:  PubMed          Journal:  J Head Trauma Rehabil        ISSN: 0885-9701            Impact factor:   2.710


  4 in total

1.  Relationship between Anterior Pituitary Volume and IGF-1 Serum Levels in Soldiers with Mild Traumatic Brain Injury History.

Authors:  Anna K Castellano; Jacob R Powell; Michael J Cools; Samuel R Walton; Randaline R Barnett; Stephen M Delellis; Richard L Goldberg; Shawn F Kane; Gary E Means; Carlos A Zamora; Patrick J Depenbrock; Jason P Mihalik
Journal:  Med Sci Sports Exerc       Date:  2022-02-08

Review 2.  Neurofilament light chain in patients with a concussion or head impacts: a systematic review and meta-analysis.

Authors:  Eleni Karantali; Dimitrios Kazis; Jack McKenna; Symela Chatzikonstantinou; Fivos Petridis; Ioannis Mavroudis
Journal:  Eur J Trauma Emerg Surg       Date:  2021-05-18       Impact factor: 3.693

3.  Potential Progression Mechanism and Key Genes in Early Stage of mTBI.

Authors:  Hu Zhou; Xue Han; Hui-Xia Zhou; Zhen-Zhen Cao; Li Yang; Jian-Yun Yu
Journal:  Evid Based Complement Alternat Med       Date:  2022-08-03       Impact factor: 2.650

4.  Long-Term Effects of Repeated Blast Exposure in United States Special Operations Forces Personnel: A Pilot Study Protocol.

Authors:  Brian L Edlow; Yelena G Bodien; Timothy Baxter; Heather G Belanger; Ryan J Cali; Katryna B Deary; Bruce Fischl; Andrea S Foulkes; Natalie Gilmore; Douglas N Greve; Jacob M Hooker; Susie Y Huang; Jessica N Kelemen; W Taylor Kimberly; Chiara Maffei; Maryam Masood; Daniel P Perl; Jonathan R Polimeni; Bruce R Rosen; Samantha L Tromly; Chieh-En J Tseng; Eveline F Yao; Nicole R Zürcher; Christine L Mac Donald; Kristen Dams-O'Connor
Journal:  J Neurotrauma       Date:  2022-06-29       Impact factor: 4.869

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.